We assign a fundamental rating of 4 out of 10 to CRNX. CRNX was compared to 191 industry peers in the Pharmaceuticals industry. While CRNX has a great health rating, there are worries on its profitability. While showing a medium growth rate, CRNX is valued expensive at the moment.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.38% | ||
| ROE | -39.46% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 22.74 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 15.12 | ||
| Quick Ratio | 15.12 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
53.24
-0.1 (-0.19%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3291.17 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.71 | ||
| P/tB | 4.71 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.38% | ||
| ROE | -39.46% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 171.91% | ||
| Cap/Sales | 412.57% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 15.12 | ||
| Quick Ratio | 15.12 | ||
| Altman-Z | 22.74 |
ChartMill assigns a fundamental rating of 4 / 10 to CRNX.
ChartMill assigns a valuation rating of 0 / 10 to CRINETICS PHARMACEUTICALS IN (CRNX). This can be considered as Overvalued.
CRINETICS PHARMACEUTICALS IN (CRNX) has a profitability rating of 1 / 10.